DSM Sinochem Pharmaceuticals (DSP) has announced that the High Court of Delhi has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement in India.
Legal outcome
The permanent injunction prevents the manufacture, use, importation, offering for sale and sale of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient (API) in India, as well as any product that uses the API.
“DSP welcomes the court’s decision,” stressed Karl Rotthier, CEO at DSP. “The lawsuit is intented to protect DSP’s world class intellectual property portfolio relating to our innovative, sustainable and environmentally friendly amoxicillin technology. DSP will continue to rigorously enforce its IP assets worldwide as it continues to invest in its innovative R&D programmes directed to enzymatic, sustainable antimicrobials and statins.”